Caspase 7
Caspase 7 is an executioner cysteine protease that cleaves after aspartate residues and participates in programmed cell death and inflammation[1][2]. Mechanistically, death receptor and DNA-damage pathways activate caspase 7 through caspase 8 and caspase 9, placing it within apoptosis signaling cascades[1]. In Fas-stimulated Jurkat cells, caspase 8 activates caspase 3 and caspase 7, supporting a branched protease cascade during apoptotic execution[3]. In inflammatory models, caspase 1 inflammasomes activate caspase 7, and caspase 7 can mediate caspase 1-induced apoptosis upstream of caspase 3[1][4]. Disease and model evidence links caspase 7 to endotoxemia resistance in deficient mice, Salmonella-infected macrophages, neuropathic rat spinal cord apoptosis, and CHO-cell viability studies[1][4][5][6]. Compared with caspase 3, caspase 7 shares substrate recognition and some endogenous substrates, but specific substrates, caspase 1-dependent activation, and endotoxemia phenotypes distinguish the isoforms[1]. For experimental applications, isatin sulfonamides inhibit caspases 3 and 7 and serve as PET or SPECT apoptosis-imaging recognition units after radiolabeling[7].
References:
- [1]. Lamkanfi M, et al. Caspase-7: a protease involved in apoptosis and inflammation. Int J Biochem Cell Biol. 2010 Jan;42(1):21-4. [Content Brief]
- [2]. Denault JB, et al. Caspases. Curr Protoc Protein Sci. 2002 Feb;Chapter 21:21.8.1-21.8.16. [Content Brief]
- [3]. Hirata H, et al. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med. 1998 Feb 16;187(4):587-600. [Content Brief]
- [4]. Mahib MR, et al. Caspase-7 mediates caspase-1-induced apoptosis independently of Bid. Microbiol Immunol. 2020 Feb;64(2):143-152. [Content Brief]
- [5]. Siniscalco D, et al. Involvement of subtype 1 metabotropic glutamate receptors in apoptosis and caspase-7 over-expression in spinal cord of neuropathic rats. Pharmacol Res. 2008 Mar;57(3):223-33. [Content Brief]
- [6]. Safari F, et al. Caspase-7 deficiency in Chinese hamster ovary cells reduces cell proliferation and viability. Biol Res. 2020 Nov 13;53(1):52. [Content Brief]
- [7]. Limpachayaporn P, et al. Isatin sulfonamides: potent caspases-3 and -7 inhibitors, and promising PET and SPECT radiotracers for apoptosis imaging. Future Med Chem. 2015;7(9):1173-96. [Content Brief]
All Product Categories
-
Caspase 7 Related Products (110)
Related Products (110)
-
Recombinant Proteins (1)
-
Antibodies (1)
-
FS102
0 ImagesCat. No.: HY-P991235Synonyms: BMS-986186FS102 is a selective Fc fragment with antigen binding (Fcab) that targets HER2 with a KD value of 0.8 nM. FS102 induces the degradation of HER2, activates Caspase 3/7 and disrupts the integrity of the cell membrane, triggering apoptosis of tumor cells. FS102 is promising for research of cancers such as breast cancer, gastric cancer, and colorectal cancer.
-
d-(KLAKLAK)2, Proapoptotic Peptide acetate
0 ImagesCat. No.: HY-P10370BPurity: 98.21%d-(KLAKLAK)2, Proapoptotic Peptide acetate is a pro-Apoptotic peptide whose core mechanism of action is to disrupt organelle membranes, especially mitochondrial membranes, thereby inducing apoptosis. d-(KLAKLAK)2, Proapoptotic Peptide acetate activates the activity of caspase 3/7 in cancer cells. Although d-(KLAKLAK)2 Proapoptotic Peptide acetate exhibits very low toxicity to eukaryotic cells extracellularly, it cannot effectively penetrate cell membranes to enter the cytoplasm on its own. d-(KLAKLAK)2, Proapoptotic Peptide acetate must be conjugated with a carrier capable of "homing" and "internalization" to exert its anti-cancer effects.
-
HDAC-IN-100
0 ImagesCat. No.: HY-P11678CAS No.: 2390474-88-9HDAC-IN-100 is a histone deacetylase inhibitor with an IC50 of 0.038 μM against HDAC1, 0.283 μM against HDAC2, and 0.586 μM against HDAC3. HDAC-IN-100 acts as a chemosensitizer and apoptosis inducer, activates caspase 3/7, and reverses Cisplatin (HY-17394) resistance. HDAC-IN-100 exerts antiproliferative effects in ovarian cancer cells and squamous cancer cells. HDAC-IN-100 is applicable for research related to ovarian cancer, squamous cell carcinoma, and Cisplatin (HY-17394)-resistant squamous cell carcinoma.
-
Ly101-4B
0 ImagesCat. No.: HY-164184CAS No.: 1415728-94-7Ly101-4B is an apoptosis inducer and multi-target inhibitor with antiproliferative, antitumor and cycytotoxic effects. Ly101-4B reduces HSF1 expression, inhibits microRNA-214 synthesis, downregulates HSP27, HSP70 and HSP90 expression, while suppressing E2F-dependent transcriptional activity and downregulating its target genes. Ly101-4B induces caspase 3/7-mediated apoptosis by reducing DNA synthesis, inhibiting the cell cycle and G1/S phase transition, without affecting RNA synthesis or inducing necrosis. Ly101-4B is selective for pancreatic ductal adenocarcinoma cells with different genotypes and varying degrees of E2F dependence. Ly101-4B can be used in research related to epithelial ovarian cancer and pancreatic ductal adenocarcinoma.
-
Apoptosis inducer 65
0 ImagesCat. No.: HY-189411Apoptosis inducer 65 is an apoptosis inducer with antiproliferative activity against cancer cells. Apoptosis inducer 65 induces G0/G1 cell cycle arrest and intrinsic apoptosis by upregulating p53, BAX, and caspase-7, while downregulating Bcl-2. Apoptosis inducer 65 inhibits ROS, NO, TNF-α, IL-1β, and IL-6 in macrophages. Apoptosis inducer 65 can be used for research on hepatocellular carcinoma and inflammation.
-
JAK1/2-IN-3
0 ImagesCat. No.: HY-180274JAK1/2-IN-3 is a JAK1 and JAK2 inhibitor with IC50 values of 14.73 nM and 10.03 nM, respectively. JAK1/2-IN-3 induces G2/M cell cycle arrest, and induces intrinsic apoptosis via increased Bax and caspase 3/7 levels and reduced Bcl2 expression. JAK1/2-IN-3 can be used for the study of leukemia cancer, breast cancer and colon cancer.
-
HDAC1-IN-11
0 ImagesCat. No.: HY-178021HDAC1-IN-11 (Compound 6) is a HDAC1 inhibitor with an IC50 of 106.6 nM. HDAC1-IN-11 inhibits the expression of Sp1 and RAD51, thereby inducing Caspase-dependent apoptosis. HDAC1-IN-11 has antitumor activity and sensitizes Etoposide (HY-13629) and Gemcitabine (HY-17026), promoting synergistic death of NSCLC cells through the inhibition of homologous recombination and non-homologous end joining (NHEJ) pathways involved in DNA DSB repair. HDAC1-IN-11 can be used for chemotherapy of cancers like NSCLC research.
-
HIF-2α-IN-17
0 ImagesCat. No.: HY-W470101CAS No.: 861212-49-9HIF-2α-IN-17 is a selective hypoxia-inducible factor 2α (HIF2α) inhibitor that binds to the PAS-B domain of HIF2α. HIF-2α-IN-17 disrupts the interaction between HIF2α and the molecular chaperone Hsp70, leading to proteasomal degradation of HIF2α. HIF-2α-IN-17 exhibits antitumor activity and induces apoptosis in cancer cells. HIF-2α-IN-17 is applicable for research on cancers such as clear cell renal cell carcinoma.
-
Antitumor agent-214
0 ImagesCat. No.: HY-181720CAS No.: 1911631-77-0Antitumor agent-214 is a chalcone analogue with anti-tumor activity. Antitumor agent-214 induces cell cycle arrest and apoptosis in tumor cells, disrupts mitochondrial metabolism, and upregulates the expression of caspase 3, caspase 7 and caspase 9, downregulates PARP1. Antitumor agent-214 can be used for anti-tumor research related to colorectal cancer, breast cancer, lung cancer, and cervical cancer.
-
Caspase-3/7 activator 4
0 ImagesCat. No.: HY-181163Caspase-3/7 activator 4 is a caspase-3 activator and caspase-7 activator. Caspase-3/7 activator 4 inhibits key enzymes in estrogen biosynthesis, including aromatase (IC50 = 38.3 nM) and steroid sulfatase (IC50 = 12.7 µM), and selectively suppresses COX-2 (IC50 = 5.38 µM). Caspase-3/7 activator 4 shows strong antioxidant activity (DPPH: IC50 = 16.26 µM). Caspase-3/7 activator 4 inhibits estrogen synthesis, suppresses estrogen availability, reduces prostaglandin production, increases caspase-3/7 expression, induces G0/G1 cell cycle arrest, induces apoptotic cell death, reduces circulating TNF-α and VEGFR-II levels, restores hepatorenal function markers and histoarchitecture, restores antioxidant defense enzyme activity, reduces lipid peroxidation, exerts antiproliferative activity against breast cancer cells, exerts antitumor activity in the Ehrlich ascites carcinoma models. Caspase-3/7 activator 4 can be used for the research of breast cancer, ehrlich ascites carcinoma.
-
Anticancer agent 64
0 ImagesCat. No.: HY-147514CAS No.: 2387902-92-1Anticancer agent 64 (compound 5m) shows cytotoxic activity in CCRF-CEM cells, with IC50 of 2.4 μM. Anticancer agent 64 shows good anticancer activity through apoptosis induction. Anticancer agent 64 induces caspase 3 and 7 activation and PARP cleavage. Anticancer agent 64 induces significant effect of mitochondria depolarization.
-
STK899704
0 ImagesCat. No.: HY-120339CAS No.: 1578247-29-6STK899704 is a tubulin polymerization inhibitor. STK899704 exhibits broad-spectrum inhibitory activity against various cancer cell lines with IC50 values ranging from 0.2 to 1.0 μM. STK899704 disrupts the mitotic spindle structure, inducing G2/M phase cell cycle arrest. STK899704 inhibits the migration ability of HT29 cells by downregulating the FAK-MEK-ERK signaling pathway, thereby suppressing the expression and activity of MMP-2 and MMP-9. STK899704 activates caspase-3/7/8/9, leading to PARP cleavage and inducing apoptosis. STK899704 induces cellular senescence through the p53 pathway. STK899704 can be used in research on skin cancer, lung cancer, colon cancer, and other cancers.
-
CK2-TN03
0 ImagesCK2-TN03 is an ATP-competitive casein kinase 2 (CK2) inhibitor, with an IC50 of 165 nM and a Ki of 20 nM. CK2-TN03 inhibits CK2-mediated survivin activation and reduces CK2-dependent phosphorylation levels of BRD4/MYCN and AKT1. CK2-TN03 exerts anti-neuroblastoma effects by inhibiting survivin, leading to mitotic catastrophe and apoptosis of cancer cells. CK2-TN03 can be used in studies related to neuroblastoma.
-
Bcl-2-IN-6
0 ImagesCat. No.: HY-144791CAS No.: 3027734-50-2Bcl-2-IN-6 (compound 10) is a potent Bcl-2 (B-cell lymphoma-2) inhibitor. Bcl-2-IN-7 down-regulates the expression of Bcl-2, and increases the expression of p53, Bax, and caspase-7 mRNA. Bcl-2-IN-7 induces cell cycle arrest and apoptosis in breast cancer MCF-7 cells. Bcl-2-IN-7 shows good anticancer activity, with IC50 values of 20.91, 22.30, 42.29, and 48.00 μM against MCF-7, LoVo, HepG2, and A549 cell lines, respectively.
-
Lb54
0 ImagesCat. No.: HY-181168Lb54 is a caspase-3 and caspase-7 activator with an EC50 of 660.9 nM for human procaspase-3. Lb54 activates caspase-3/7, which cleaves Gasdermin D (GSDMD) at aspartic acid residue 87 to generate a p10 fragment, preventing formation of the pore-forming p30 fragment of GSDMD. Lb54 suppresses GSDMD-mediated pyroptosis through caspase-3/7 activation, thereby attenuating inflammatory responses and conferring protection against sepsis. Lb54 alleviates acute lung injury, and inhibited systemic inflammation by restraining the maturation of monocyte-derived dendritic cells. Lb54 can be used for the research of sepsis.
-
Ac-DEVD-CHO TFA
0 ImagesCat. No.: HY-P1001AAc-DEVD-CHO TFA is a peptide inhibitor of caspase-3 (Ki=230 pM) and caspase-7. Ac-DEVD-CHO TFA reduces caspase-3 activity and apoptosis induced by Prostaglandin E2 (HY-101952) in rat cortical neurons. Ac-DEVD-CHO TFA is promising for research of neurodegenerative diseases and cancers.
-
Bcl-2-IN-7
0 ImagesCat. No.: HY-144792CAS No.: 3027734-46-6Bcl-2-IN-7 (compound 6) is a potent Bcl-2 (B-cell lymphoma-2) inhibitor. Bcl-2-IN-7 down-regulates the expression of Bcl-2, and increases the expression of p53, Bax, and caspase-7 mRNA. Bcl-2-IN-7 induces cell cycle arrest and apoptosis in breast cancer MCF-7 cells. Bcl-2-IN-7 shows good anticancer activity, with IC50 values of 20.17, 22.64, 45.57, and 51.50 μM against MCF-7, LoVo, HepG2, and A549 cell lines, respectively.
-
Apoptosis inducer 52
0 ImagesCat. No.: HY-179124Apoptosis inducer 52 is a derivative of flutamide that induces apoptosis in prostate cancer cells. Apoptosis inducer 52 promotes apoptosis by activating both intrinsic and extrinsic apoptotic pathways, without generating reactive oxygen species (ROS). Apoptosis inducer 52 triggers caspase 3/7 activity and the externalization of phosphatidylserine, leading to cell cycle arrest at the G0/G1 phase. Apoptosis inducer 52 can be used for the research of androgen receptor (AR)-dependent and -independent prostate cancers and leukemia.
-
SV119
0 ImagesCat. No.: HY-177345CAS No.: 913815-82-4SV119 is a selective sigma-2 (σ₂) receptor ligand (Ki ≈ 5-10 nM). SV119 induces apoptosis in various human cancer cell lines by activating caspase-3 and promoting mitochondrial depolarization. SV119 can enhance the effects of chemotherapeutic agents such as Paclitaxel (HY-B0015), increasing their cytotoxicity against tumor cells. SV119 significantly inhibits tumor growth in mouse xenograft models, both alone and in combination. SV119 is useful in the research of cancers such as breast, prostate, and pancreatic cancer.
